Featured Video

20% Subcutaneous Immunoglobulin for Maintenance Treatment in Chronic Inflammatory Demyelinating Polyneuropathy (PATH): a Randomized, Double-blind, Placebo-controlled, Phase 3 Trial
Vera Bril, BSc, FRCPC, MD
University of Toronto,Toronto, Canada
15:31 MIN
  • CIDP
Learn about the PATH study results and SCIG (subcutaneous immunoglobulin) treatment in CIDP

Our Experts

Kenneth C. Gorson, M.D.
Tufts University School of Medicine
Kenneth C. Gorson, M.D.
Kenneth C. Gorson, M.D.
Tufts University School of Medicine
  • GBS
Kenneth C. Gorson, M.D. is a Professor of Neurology in the Department of Neurology at St. Elizabeth’s Medical Center, Tufts University School of Medicine, in Boston.
Karissa Gable, MD
Duke University Medical Center in Durham, North Carolina
Karissa Gable, MD
Karissa Gable, MD
Duke University Medical Center in Durham, North Carolina
  • CIDP
Dr. Karissa Gable is a Neuromuscular specialist at Duke University Medical Center in Durham, North Carolina.
Jonathan S. Katz, MD
Forbes Norris MDA/ALS Research Center at the California Pacific Medical Center in San Francisco, California
Jonathan S. Katz, MD
Jonathan S. Katz, MD
Forbes Norris MDA/ALS Research Center at the California Pacific Medical Center in San Francisco, California
  • MMN
Jonathan S. Katz, MD, is the Director, Forbes Norris MDA/ALS Research Center at the California Pacific Medical Center in San Francisco, California.
Claudia Sommer, MD
University of Würzburg, Würzburg, Germany
Claudia Sommer, MD
Claudia Sommer, MD
University of Würzburg, Würzburg, Germany
  • MMN
Claudia Sommer is a Professor of Neurology at the University of Würzburg, Germany.
Back to Top